搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
15 小时
Best Patch Management Software (2025): Compare Features & Pricing
Explore the best patch management software options in 2025. Compare features, pricing, and reviews to find the right tool for ...
Microsoft
22 小时
Microsoft Intune Enterprise Application Management
Discover, package, and update apps directly from the Intune console. Unify mission-critical advanced endpoint management and security solutions with the Intune Suite. All products included in the ...
12 小时
Cybersecurity Trends And Priorities To Watch For 2025
As each year passes, the complexities of cybersecurity and the more sophisticated threats grow. Two tech trends will be ...
14 小时
CrowdStrike: A Masterclass In Innovation And Sales
CrowdStrike recently surpassed over $1 billion in quarterly sales for the first time in its history. Click here to find out ...
PCQuest
21 小时
AI-Powered Cybersecurity: The Silent Guardian of Our Digital Lives
Discover how AI is transforming cybersecurity, tackling phishing, ransomware, and more with speed and precision to protect ...
The Register on MSN
17 小时
What do ransomware and Jesus have in common? A birth month and an unwillingness to die
Dr Popp, originally from Ohio, was an evolutionary biologist and researcher whose work, much of which was carried out in ...
GlobalData on MSN
19 小时
AstraZeneca’s Tagrisso gains EC approval for NSCLC treatment
AstraZeneca has gained approval from the European Commission for its oral therapy, Tagrisso (osimertinib), to treat adults with NSCLC.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈